Edesa Biotech illékonyság
Mi az Edesa Biotech illékonyság?
A illékonyság az Edesa Biotech, Inc. - 7.10%
Mi a illékonyság meghatározása?
A volatilitás vagy az átlagos valódi tartomány százalék (ATRP 14) a záróár százalékában kifejezve.
Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.
The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.
Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets
illékonyság a Health Care szektor a NASDAQ-on cégekben a Edesa Biotech -hoz képest
Mit csinál Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
illékonyság -hoz hasonló cégek Edesa Biotech
- SME Credit Realisation Fund nak illékonyság 7.09% van
- Archer Materials nak illékonyság 7.09% van
- Nagreeka Capital & Infrastructure nak illékonyság 7.09% van
- Synairgen plc nak illékonyság 7.09% van
- Youdao nak illékonyság 7.09% van
- Oricon Enterprises nak illékonyság 7.09% van
- Edesa Biotech nak illékonyság 7.10% van
- Dillistone Plc nak illékonyság 7.11% van
- New Momentum nak illékonyság 7.11% van
- Globalstar nak illékonyság 7.11% van
- Ludlow Jute & Specialities nak illékonyság 7.11% van
- Salona Global Medical Device nak illékonyság 7.11% van
- Summit Therapeutics Inc nak illékonyság 7.11% van